Antonella Tosco

TL;DR: It is reported that oral treatment with cysteamine greatly reduces the mortality rate and improves the phenotype of newborn mice bearing the F508del-CFTR mutation, and optimal schedules of cysteamines plus EGCG might be used for the treatment of CF caused by the F504del- CFTR mutation.

TL;DR: Most of the patients with serum antiendomysium antibodies and normal jejunal histology showed immunohistochemical signs of immune activation in the epithelium, lamina propria, and crypts.

TL;DR: Intestinal deposits of anti-TG2 IgA identify children at risk for villous atrophy, and most children with potential celiac disease remain healthy.

TL;DR: A sizeable proportion of asymptomatic potential celiac patients showed fluctuation or negativization of antibody production, and many of these, with persistently positive anti-TG2, did not develop mucosal damage after 9 years of follow-up.

TL;DR: The proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation is provided and the results suggest that the combination treatment of cysteamine plus EGCG acts ‘on-target’ because it can only rescueCFTR function when autophagy is functional and improves CFTRfunction when a rescuable protein is expressed.